Ana I. Perez‐Caballero

ORCID: 0000-0001-6315-1453
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nutritional Studies and Diet
  • Cardiovascular Disease and Adiposity
  • Cardiovascular Health and Disease Prevention
  • Lipid metabolism and disorders
  • Cardiovascular Function and Risk Factors
  • Diet and metabolism studies
  • Consumer Attitudes and Food Labeling
  • Liver Disease Diagnosis and Treatment
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Diet, Metabolism, and Disease
  • Cancer, Lipids, and Metabolism
  • Fatty Acid Research and Health
  • Edible Oils Quality and Analysis
  • Adipokines, Inflammation, and Metabolic Diseases
  • Cerebrovascular and Carotid Artery Diseases
  • Adipose Tissue and Metabolism
  • Genetic Neurodegenerative Diseases
  • Long-Term Effects of COVID-19
  • Metabolism, Diabetes, and Cancer
  • Cystic Fibrosis Research Advances
  • COVID-19 Clinical Research Studies
  • Nuts composition and effects
  • RNA modifications and cancer
  • Advanced Glycation End Products research
  • Phytochemicals and Antioxidant Activities

Hospital Universitario Reina Sofía
2012-2022

University of Córdoba
2012-2021

Instituto Maimónides de Investigación Biomédica de Córdoba
2012-2021

Instituto de Salud Carlos III
2012-2021

Centro de Investigación Biomédica en Red
2014-2016

North York General Hospital
2016

University of Toronto
2016

Javier Delgado‐Lista Juan F. Alcalá‐Díaz José D. Torres‐Peña Gracia M. Quintana‐Navarro Francisco Fuentes and 86 more Antonio García‐Ríos Ana M. Ortiz-Morales Ana I. Gonzalez-Requero Ana I. Perez‐Caballero Elena M. Yubero‐Serrano Oriol Alberto Rangel-Zúñiga Antonio Camargo Fernando Rodríguez-Cantalejo Fernando Lopez‐Segura Lina Badimón José M. Ordovás Francisco Pérez‐Jiménez Pablo Pérez‐Martínez José López‐Miranda Juan F. Alcalá‐Díaz Yolanda Almaden Peña Enrique Aranda Antonio P. Arenas-de Larriva Lina Badimón Juan J. Badimón Ángeles Blanco‐Molina Ruth Blanco-Rojo Julia Bolivar-Muñoz Javier Caballero‐Villarraso Antonio Camargo Javier Emílio Lazo Chica Andreea Corina Juan Criado-García Cristina Cruz‐Teno Antonio Daponte Eduardo de Teresa Galván Nieves Delgado‐Casado Javier Delgado‐Lista Ramón Estruch Juan Marcelo Fernández Carolina Fernández-Gandara Francisco Fuentes Sonia García‐Carpintero Antonio García‐Ríos Francisco Gómez-Delgado Angela Gomez-Garduño Purificación Gómez-Luna Maria J. Gómez-Luna Lorena González-Guardia Ana I. Gonzalez-Requero Francisco M. Gutierrez‐Mariscal Carmen Haro Rosa Jiménez-Lucena Ana Isabel Jiménez-Morales Ana Leon‐Acuña José López‐Miranda Fernando Lopez‐Segura Carmen Marín-Hinojosa María E. Meneses Dolores Mesa-Luna Maria N Moya-Garrido Ignacio Muñoz-Carvajal Vanessa Navarro-Martos Juan J Ochoa José M. Ordovás Juan A Ortiz-Minuesa Ana M. Ortiz-Morales Manuel Pan Patricia J. Peña‐Orihuela Ana I. Perez‐Caballero Isabel Perez-Corral Francisco Pérez‐Jiménez Pablo Pérez‐Martínez Francesc X Pi-Sunyer Gracia M. Quintana‐Navarro Irene Ramirez-Lara Oriol Alberto Rangel-Zúñiga Fernando Rodríguez‐Artalejo Fernando Rodríguez-Cantalejo Miguel A. Romero Irene Roncero‐Ramos Juan Ruano Joaquín Ruiz de Castroviejo Pablo Sánchez‐Villegas José Suárez de Lezo José Suárez de Lezo José D. Torres‐Peña Cristina Vals‐Delgado Roberto Valverde Francesco Visioli Elena M. Yubero‐Serrano

10.1016/s0140-6736(22)00122-2 article EN publisher-specific-oa The Lancet 2022-05-01

Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk patients hospitalized because COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed between 5 February and May 2020 in five hospitals South Spain. Intervention: received (25-hydroxyvitamin D3) (0.266 mg/capsule, 2 capsules...

10.3390/nu13061760 article EN Nutrients 2021-05-21

Abstract Background We examined the degree of postprandial triglyceride ( TG ) response over day, representing a highly dynamic state, with continuous metabolic adaptations, among normal‐weight, overweight and obese patients, according to their metabolically healthy or abnormal status. Materials methods A total 1002 patients from CORDIOPREV clinical trial NCT 00924937) were submitted an oral fat load test meal 0·7 g fat/kg body weight (12% saturated fatty acids SFA ), 10% polyunsaturated...

10.1111/eci.12339 article EN European Journal of Clinical Investigation 2014-09-18

TCF7L2 rs7903146 is an important genetic factor predicting type 2 diabetes (T2DM) which has also been linked to higher cardiovascular risk. To date, there little information about the additional impact of this single nucleotide polymorphism (SNP) beyond glucose metabolism.We studied whether influenced postprandial lipid metabolism in three different populations (healthy young men, metabolic syndrome (MetS) patients and elderly persons). Eighty-eight healthy males were submitted a saturated...

10.1371/journal.pone.0043390 article EN cc-by PLoS ONE 2012-08-20

Rationale: Metabolic syndrome (MetS) is a high-prevalence condition characterized by altered energy metabolism, insulin resistance, and elevated cardiovascular risk. Objectives: Although many individual single nucleotide polymorphisms (SNPs) have been linked to certain MetS features, there are few studies analyzing the influence of SNPs on carbohydrate metabolism in MetS. Methods: A total 904 (tag functional SNPs) were tested for 8 fasting dynamic markers performance an intravenous glucose...

10.1210/jc.2013-3165 article EN The Journal of Clinical Endocrinology & Metabolism 2013-11-08

Background Recent data suggest that the presence of associated metabolic abnormalities may be important modifiers association obesity with a poorer prognosis in coronary heart disease. We determined influence isolated overweight and on carotid intima media thickness (IMT-CC), also assessed whether this was by abnormalities. Methods 1002 participants from CordioPrev study were studied at entry. their phenotypes performed ultrasound assessment. evaluated obesity, IMT-CC. Results Metabolically...

10.1371/journal.pone.0153096 article EN public-domain PLoS ONE 2016-04-11

<h3>Background</h3> Huntington’s disease (HD) is caused by an expanded CAG trinucleotide repeat within the Huntingin gene, with affected individuals inheriting &gt;36 repeats. Intermediate alleles (IAs) are classed as 27–35 Although IAs do not fall causing range, they susceptible to paternal germline instability, and so may expand into reduced penetrance or full mutation range upon transmission next generation. There several factors which thought influence instability. However, risk of...

10.1136/jnnp-2016-314597.220 article EN Journal of Neurology Neurosurgery & Psychiatry 2016-09-01
Coming Soon ...